GlassScriptPhysician profile
Bradley J Zehring
NPI 1114363561
$2,619.62
in general payments reported to CMS, 2019-2025
19 companies · $1,262 in 2025
The $1,262 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $250 · 2021: $196 · 2022: $168 · 2023: $42.47 · 2025: $1,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $363.09 | 2019-2025 | Fanapt |
| Allergan, INC. | $318.69 | 2019-2020 | |
| Lundbeck LLC | $305.14 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $257.70 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $255.26 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $239.65 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $152.39 | 2025 | Auvelity, Sunosi |
| Corium, LLC | $146.03 | 2025 | Azstarys |
| Abbvie INC. | $124.93 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $87.85 | 2025 | Austedo Xr |
| Tris Pharma INC | $75.11 | 2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $67.78 | 2020-2025 | |
| Alfasigma USA, INC. | $57.26 | 2021 | |
| Shire North American Group INC | $53.55 | 2019 | |
| Almatica Pharma LLC | $44.57 | 2022-2023 | Sertraline Hcl, Loreev Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $27.07 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.94 | 2025 | Qelbree |
| Noven Therapeutics, LLC | $14.67 | 2025 | Xelstrym |
| Alkermes, INC. | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Zehring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.